Author

Yanke Liang

Institution: C4 Therapeutics (United States)

Observed institution: C4 Therapeutics (United States)

ORCID: 0009-0006-5539-9946

Observed ORCID: 0009-0006-5539-9946

OpenAlex ID: A5014296652

Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers

2022 · Mathew E. Sowa, Bridget Kreger, et al. · Cancer Research · 12

CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance

2025 · Bridget T. Kreger, Yanke Liang, et al. · Cancer Research · 11

Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 10

Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader

2025 · Douglas L. Orsi, Kiel E. Lazarski, et al. · RSC Medicinal Chemistry · 2

Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 2

Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

2024 · Bridget Kreger, Jacob R. Stephenson, et al. · Cancer Research · 1

Works count: 6

Citation count: 38

H-index: 3

I10-index: 3